Your browser doesn't support javascript.
loading
Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.
Kapulu, Melissa; Manda-Taylor, Lucinda; Balasingam, Shobana; Means, Gary; Ayiro Malungu, Mikal; Bejon, Philip; Chi, Primus Che; Chiu, Christopher; Church, E Chandler; Correa-Oliveira, Rodrigo; Day, Nicholas; Durbin, Anna; Egesa, Moses; Emerson, Claudia; Jambo, Kondwani; Mathur, Roli; Metzger, Wolfram; Mumba, Noni; Nazziwa, Winfred; Olotu, Ally; Rodgers, Jacqueline; Sinyiza, Frank; Talaat, Kawsar; Kamerling, Ingrid; Weller, Charlie; Baay, Marc; Neels, Pieter.
Afiliación
  • Kapulu M; KEMRI-Wellcome Trust Research Programme, Kenya. Electronic address: mkapulu@kemri-wellcome.org.
  • Manda-Taylor L; Kamuzu University of Health Sciences, Malawi. Electronic address: mandal@kuhes.ac.mw.
  • Balasingam S; Wellcome Trust, London, UK. Electronic address: s.balasingam@wellcome.org.
  • Means G; Bill & Melinda Gates Foundation, Seattle, USA. Electronic address: gary.means@gatesfoundation.org.
  • Ayiro Malungu M; Pharmacy and Poisons Board, Kenya. Electronic address: mayilo@pharmacyboardkenya.org.
  • Bejon P; KEMRI-Wellcome Trust Research Programme, Kenya. Electronic address: pbejon@kemri-wellcome.org.
  • Chi PC; KEMRI-Wellcome Trust Research Programme, Kenya. Electronic address: pchi@kemri-wellcome.org.
  • Chiu C; Imperial College London, UK. Electronic address: c.chiu@imperial.ac.uk.
  • Church EC; Fred Hutchinson Cancer Center, Seattle, USA. Electronic address: echurch3@uw.edu.
  • Correa-Oliveira R; Fundação Oswaldo Cruz (Fiocruz), Brazil(2).
  • Day N; Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand. Electronic address: Nickd@tropmedres.ac.
  • Durbin A; Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Electronic address: adurbin1@jhu.edu.
  • Egesa M; MRC/UVRI and LSHTM Uganda Research Unit, Uganda; London School of Hygiene and Tropical Medicine, UK. Electronic address: Moses.Egesa@mrcuganda.org.
  • Emerson C; McMaster University, Institute on Ethics & Policy for Innovation, Canada. Electronic address: emersoc@mcmaster.ca.
  • Jambo K; Malawi Liverpool Wellcome Programme, Malawi. Electronic address: Kondwani.Jambo@lstmed.ac.uk.
  • Mathur R; Bioethics Unit, Indian Council of Medical Research, India. Electronic address: rolimath@gmail.com.
  • Metzger W; Eberhard Karls University, Tuebingen, Germany. Electronic address: wolfram.metzger@uni-tuebingen.de.
  • Mumba N; KEMRI-Wellcome Trust Research Programme, Kenya. Electronic address: nmumba@kemri-wellcome.org.
  • Nazziwa W; Uganda National Council for Science and Technology, Uganda. Electronic address: winnfry@gmail.com.
  • Olotu A; Ifakara Health Institute, Tanzania. Electronic address: aolotu@ihi.or.tz.
  • Rodgers J; AVAREF secretariat, WHO AFRO, Brazzaville, Congo. Electronic address: rodgersj@who.int.
  • Sinyiza F; National Health Sciences Research Committee, Malawi. Electronic address: frasinyiza@yahoo.com.
  • Talaat K; Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Electronic address: ktalaat@jhu.edu.
  • Kamerling I; Centre for Human Drug Research, Leiden, the Netherlands. Electronic address: idvisser@chdr.nl.
  • Weller C; Wellcome Trust, London, UK. Electronic address: c.weller@wellcome.org.
  • Baay M; P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address: marc.baay@p-95.com.
  • Neels P; IABS-EU, Lyon, France. Electronic address: pieter.neels@vaccine-advice.be.
Biologicals ; 85: 101747, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38350825
ABSTRACT
Earlier meetings laid the foundations for Controlled Human Infection Models (CHIMs), also known as human challenge studies and human infection studies, including Good Manufacturing Practice (GMP) production of the challenge agent, CHIM ethics, environmental safety in CHIM, recruitment, community engagement, advertising and incentives, pre-existing immunity, and clinical, immunological, and microbiological endpoints. The fourth CHIM meeting focused on CHIM studies being conducted in endemic countries. Over the last ten years we have seen a vast expansion of the number of countries in Africa performing CHIM studies, as well as a growing number of different challenge organisms being used. Community and public engagement with assiduous ethical and regulatory oversight has been central to successful introductions and should be continued, in more community-led or community-driven models. Valuable initiatives for regulation of CHIMs have been undertaken but further capacity building remains essential.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Ethics Idioma: En Revista: Biologicals Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Ethics Idioma: En Revista: Biologicals Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido